Seeking Alpha

Celgene (CELG) says a Revlimid/ dexamethasone combo met its primary PFS endpoint in a Phase III...

Celgene (CELG) says a Revlimid/ dexamethasone combo met its primary PFS endpoint in a Phase III study of newly diagnosed multiple myeloma patients. Shares +2.5% premarket. (PR)
Comments (1)
  • maven pharm
    , contributor
    Comments (135) | Send Message
     
    Celgene will be at $150.00 near term.
    11 Jul 2013, 03:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|